Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Rani Therapeutics Holdings Inc (RANI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.57+3.06%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RANI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Fund operations into Q4 2027 with cash and securities | Management plans to fund operations into Q4 2027. | Intact | Cash and securities fall short of funding operations into Q4 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Rani expects its cash, cash equivalents and marketable securities to be sufficient to fund its operations at least through 2027.” “Second Quarter 2026 Financial Results: • Cash, cash equivalents and marketable securities as of June 30, 2026 totaled $53.4 million, compared to $43.4 million as of March 31, 2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
RANI is a speculative biotechnology company, not a proven earnings compounder: it is loss-making, and recent financial performance is weak. The thesis is on watch, with management progress on product development but volatile execution and high overall risk.
The valuation model shows RANI at a substantial premium to peers, while confidence in that estimate is low. The evidence flags the premium as unjustified, and the expectations gap is meaningful, so the valuation does not appear to reflect the weak results and execution risks fully.
Near term, results remain vulnerable: the estimated miss probability is elevated, and a guidance cut or weaker employment data could add pressure. Over the multi-year view, RT-114 collaboration revenue has increased, but cash and securities have declined; management says these resources, including milestone payments, should fund operations into Q4 2027.
A key swing factor is whether management advances RT-114 and maintains enough funding to support operations, while strengthening its leadership team. The near-term setup also depends on the next guidance update and broader Healthcare momentum, including earnings and outlook from sector bellwethers.
Over the next 1 to 3 years, RANI’s long-term thesis depends on translating product-development progress into sustained execution without worsening its funding position. Weak financial performance, high risk, and a peer premium leave the evidence mixed. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stabilize leadership with new CFO appointment | The new CFO may stabilize finances after recent changes. | Improving | New CFO fails to stabilize financial operations within 1 year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of about 35% next year | Analysts expect about 35% revenue growth next year. | Improving | YoY revenue growth falls below 30% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.21 → $-0.19 · observed estimates
$0.00B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-07-25 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-07-26 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-07-27 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-07-28 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-07-29 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-07-30 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-07-31 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-01 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-02 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-08-03 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-04 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-05 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-08-06 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-07 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-08 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-08-09 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-10 | $-0.21 | $4,925,000 | 3 / 4 |
| 2026-08-12 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-13 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-14 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-15 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-16 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-17 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-18 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-19 | $-0.21 | $4,925,000 | 2 / 3 |
| 2026-08-20 | $-0.20 | $6,632,500 | 2 / 3 |
| 2026-08-21 | $-0.20 | $6,632,500 | 2 / 3 |
| 2026-08-22 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-23 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-24 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-25 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-26 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-27 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-28 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-29 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-30 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-08-31 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-01 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-02 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-03 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-04 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-05 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-06 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-07 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-08 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-09 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-10 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-11 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-12 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-13 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-14 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-15 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-16 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-17 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-18 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-19 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-20 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-21 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-22 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-23 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-24 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-25 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-26 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-27 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-28 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-29 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-09-30 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-01 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-02 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-03 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-04 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-05 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-06 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-07 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-08 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-09 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-10 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-11 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-12 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-13 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-14 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-15 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-16 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-17 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-18 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-19 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-20 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-21 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-22 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-23 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-24 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-25 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-26 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-27 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-28 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-29 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-30 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-10-31 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-11-01 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-11-02 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-11-03 | $-0.19 | $6,632,500 | 2 / 3 |
| 2026-11-04 | $-0.19 | $6,632,500 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.